2 research outputs found
Alterations in the coagulation markers did not showdifferences with the severity of COVIDâ19 in Peruvianpatients: A crossâsectional singleâcenter study
Background and Aims:COVIDâ19 is a pandemic disease that can lead to alteredlung function, systemic inflammatory events, and altered coagulation. During severestages of the disease, changes in coagulation homeostasis increase, leading tothrombosis, and increased risk of death. In this crossâsectional study, we aimedto assess coagulation markers by COVIDâ19 severity in Peruvian adults.Methods:During the second wave of infections, we included 186 adults diagnosedwith COVIDâ19 (mean age 53.3 ± 16.3 years). Patients were divided into mild,moderate, and severe stages of COVIDâ19, and coagulation markers includedprothrombin time (PT), activated partial prothrombin time (aPTT), fibrinogen,Dâdimer, and platelet count.Results:Of the total, 120 (64.5%) were males and 39 (21%) were in the intensivecare unit. We determine 104 (55.9%), 43 (24.7%), and 36 (19.4%) patients in mild,moderate, and severe stages of COVIDâ19, respectively. In the severe stage ofCOVIDâ19, patients had an average concentration of PT, aPTT, fibrinogen,Dâdimer,and platelets of 13.2 ± 0.9 s, 28.9 ± 4.3 s, 679.4 ± 185.1 mg/dL, 1.9 ± 3.1 ÎŒg/mL, and272.8 ± 88.9 cel/10 mm,3respectively. We found no differences in the concentra-tion of each marker according to severity (p< 0.05). Patients with severe COVIDâ19had altered the aPTT, fibrinogen,Dâdimer, and PT in 31 (57.4%), 48 (88.9%), 37(68.5%), and 15 (27.8%) cases, respectively.Conclusions:Our results showed that although there is an alteration in coagulationmarkers, mainly fibrinogen andDâfiber, there are no differences in concentrationaccording to the severity of COVIDâ19
Alterations in the coagulation markers did not show differences with the severity of COVID-19 in Peruvian patients: A cross-sectional single-center study
Background and Aims:COVIDâ19 is a pandemic disease that can lead to alteredlung function, systemic inflammatory events, and altered coagulation. During severestages of the disease, changes in coagulation homeostasis increase, leading tothrombosis, and increased risk of death. In this crossâsectional study, we aimedto assess coagulation markers by COVIDâ19 severity in Peruvian adults.Methods:During the second wave of infections, we included 186 adults diagnosedwith COVIDâ19 (mean age 53.3 ± 16.3 years). Patients were divided into mild,moderate, and severe stages of COVIDâ19, and coagulation markers includedprothrombin time (PT), activated partial prothrombin time (aPTT), fibrinogen,Dâdimer, and platelet count.Results:Of the total, 120 (64.5%) were males and 39 (21%) were in the intensivecare unit. We determine 104 (55.9%), 43 (24.7%), and 36 (19.4%) patients in mild,moderate, and severe stages of COVIDâ19, respectively. In the severe stage ofCOVIDâ19, patients had an average concentration of PT, aPTT, fibrinogen,Dâdimer,and platelets of 13.2 ± 0.9 s, 28.9 ± 4.3 s, 679.4 ± 185.1 mg/dL, 1.9 ± 3.1 ÎŒg/mL, and272.8 ± 88.9 cel/10 mm,3respectively. We found no differences in the concentra-tion of each marker according to severity (p< 0.05). Patients with severe COVIDâ19had altered the aPTT, fibrinogen,Dâdimer, and PT in 31 (57.4%), 48 (88.9%), 37(68.5%), and 15 (27.8%) cases, respectively.Conclusions:Our results showed that although there is an alteration in coagulationmarkers, mainly fibrinogen andDâfiber, there are no differences in concentrationaccording to the severity of COVIDâ1